|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US5521063A
(en)
|
1985-03-15 |
1996-05-28 |
Antivirals Inc. |
Polynucleotide reagent containing chiral subunits and methods of use
|
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
WO1986005519A1
(en)
|
1985-03-15 |
1986-09-25 |
James Summerton |
Polynucleotide assay reagent and method
|
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
AU659482B2
(en)
|
1991-06-28 |
1995-05-18 |
Massachusetts Institute Of Technology |
Localized oligonucleotide therapy
|
|
WO1997022371A1
(en)
|
1995-12-18 |
1997-06-26 |
Collagen Corporation |
Crosslinked polymer compositions and methods for their use
|
|
US6245747B1
(en)
|
1996-03-12 |
2001-06-12 |
The Board Of Regents Of The University Of Nebraska |
Targeted site specific antisense oligodeoxynucleotide delivery method
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
US7053207B2
(en)
|
1999-05-04 |
2006-05-30 |
Exiqon A/S |
L-ribo-LNA analogues
|
|
CA2459347C
(en)
|
2001-09-04 |
2012-10-09 |
Exiqon A/S |
Locked nucleic acid (lna) compositions and uses thereof
|
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
KR100464261B1
(ko)
|
2002-01-24 |
2005-01-03 |
주식회사 파나진 |
Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
|
|
KR20030084444A
(ko)
|
2002-04-26 |
2003-11-01 |
주식회사 파나진 |
Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
|
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
|
AU2003287464A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
2'-fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
|
US7468418B2
(en)
|
2003-04-29 |
2008-12-23 |
Avi Biopharma., Inc. |
Compositions for enhancing transport of molecules into cells
|
|
US7211668B2
(en)
|
2003-07-28 |
2007-05-01 |
Panagene, Inc. |
PNA monomer and precursor
|
|
PL2735568T3
(pl)
|
2006-05-10 |
2018-02-28 |
Sarepta Therapeutics, Inc. |
Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami
|
|
CA2693742A1
(en)
|
2007-07-12 |
2009-01-15 |
Prosensa Technologies B.V. |
Molecules for targeting compounds to various selected organs, tissues or tumor cells
|
|
RU2606627C2
(ru)
|
2007-11-15 |
2017-01-10 |
Серепта Терапьютикс,Инк. |
Способ синтеза морфолиновых олигомеров
|
|
US8076476B2
(en)
|
2007-11-15 |
2011-12-13 |
Avi Biopharma, Inc. |
Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
|
|
US8299206B2
(en)
|
2007-11-15 |
2012-10-30 |
Avi Biopharma, Inc. |
Method of synthesis of morpholino oligomers
|
|
CN102282155B
(zh)
|
2008-12-02 |
2017-06-09 |
日本波涛生命科学公司 |
磷原子修饰的核酸的合成方法
|
|
CA2758189C
(en)
|
2009-04-10 |
2020-12-29 |
Association Institut De Myologie |
Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
|
|
RU2612521C2
(ru)
|
2009-07-06 |
2017-03-09 |
Онтории, Инк. |
Новые пролекарства нуклеиновых кислот и способы их применения
|
|
ES2586683T3
(es)
|
2009-09-16 |
2016-10-18 |
Wave Life Sciences Japan, Inc. |
Grupo protector novedoso para sintetizar ARN y derivados del mismo
|
|
KR20200133284A
(ko)
|
2010-05-28 |
2020-11-26 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
JP5868324B2
(ja)
|
2010-09-24 |
2016-02-24 |
株式会社Wave Life Sciences Japan |
不斉補助基
|
|
CA3092114A1
(en)
|
2011-05-05 |
2012-11-08 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
PL2581448T3
(pl)
|
2011-10-13 |
2015-08-31 |
Association Inst De Myologie |
Tricyklo-tiofosforanowy DNA
|
|
WO2013086207A1
(en)
|
2011-12-06 |
2013-06-13 |
The Ohio State University |
Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
|
|
NZ627896A
(en)
|
2012-01-27 |
2016-11-25 |
Biomarin Technologies B V |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
DE102012101676A1
(de)
|
2012-02-29 |
2013-08-29 |
Klaus-Dieter Rösler |
Verfahren und Vorrichtung zum Bearbeiten von Formularen mit einer Datenverarbeitungsanlage
|
|
PL2872485T3
(pl)
|
2012-07-13 |
2021-05-31 |
Wave Life Sciences Ltd. |
Asymetryczna grupa pomocnicza
|
|
KR102213609B1
(ko)
|
2012-07-13 |
2021-02-08 |
웨이브 라이프 사이언시스 리미티드 |
키랄 제어
|
|
KR101696704B1
(ko)
*
|
2013-12-17 |
2017-01-16 |
주식회사 인코드젠 |
오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도
|
|
US10322173B2
(en)
|
2014-01-15 |
2019-06-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
|
JPWO2015108047A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
BR112016016400A2
(pt)
|
2014-01-16 |
2017-10-03 |
Wave Life Sciences Ltd |
Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
|
|
KR102524543B1
(ko)
*
|
2014-06-10 |
2023-04-20 |
에라스무스 유니버시티 메디컬 센터 로테르담 |
폼페병의 치료에 유용한 안티센스 올리고뉴클레오티드
|
|
AU2015338923B2
(en)
|
2014-11-02 |
2021-10-21 |
Arcturus Therapeutics, Inc. |
Messenger UNA molecules and uses thereof
|
|
EP3262056A4
(en)
*
|
2015-02-27 |
2018-09-19 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
|
IL320434A
(en)
|
2015-07-22 |
2025-06-01 |
Wave Life Sciences Ltd |
Oligonucleotide preparations and methods
|
|
IL295755A
(en)
|
2015-10-09 |
2022-10-01 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
WO2017184529A1
(en)
*
|
2016-04-18 |
2017-10-26 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
EP3452596A4
(en)
|
2016-05-04 |
2020-03-18 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
|
|
CN109462995A
(zh)
|
2016-05-04 |
2019-03-12 |
波涛生命科学有限公司 |
生物活性剂的方法和组合物
|
|
NL2017294B1
(en)
*
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
|
US11555189B2
(en)
*
|
2017-10-18 |
2023-01-17 |
Sarepta Therapeutics, Inc. |
Antisense oligomer compounds
|